This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
blood donors | 1063 |
blood transfusion | 772 |
whole blood | 705 |
red blood | 596 |
study design | 559 |
blood components | 542 |
blood donation | 528 |
summary conclusions | 490 |
case studies | 489 |
background case | 481 |
blood group | 478 |
blood products | 466 |
red cell | 464 |
blood bank | 420 |
blood cells | 397 |
design method | 387 |
results finding | 375 |
nucleic acid | 343 |
transfusion medicine | 338 |
test results | 330 |
blood cell | 311 |
public health | 299 |
blood donor | 297 |
specific ige | 288 |
granted medrxiv | 285 |
author funder | 285 |
significantly higher | 284 |
red cells | 279 |
control group | 279 |
allergic rhinitis | 277 |
copyright holder | 277 |
mg kg | 273 |
lateral flow | 267 |
made available | 261 |
adverse events | 258 |
blood samples | 255 |
statistically significant | 250 |
version posted | 246 |
significant difference | 244 |
transfusion reactions | 241 |
mg dl | 240 |
platelet concentrates | 239 |
flow cytometry | 236 |
international license | 230 |
infectious diseases | 219 |
diagnostic tests | 214 |
transfusion service | 209 |
blood banks | 205 |
platelet count | 203 |
bone marrow | 202 |
risk factors | 200 |
mean age | 200 |
significant differences | 198 |
iu ml | 198 |
performed using | 198 |
ng ml | 196 |
health care | 191 |
blood donations | 188 |
mg ml | 187 |
medrxiv preprint | 186 |
years old | 180 |
blood center | 178 |
blood units | 178 |
blood collection | 175 |
quality control | 173 |
united states | 172 |
infectious disease | 169 |
pregnant women | 164 |
least one | 162 |
skin prick | 162 |
positive results | 159 |
blood supply | 157 |
two groups | 156 |
total number | 155 |
peer review | 155 |
case report | 154 |
pg ml | 152 |
test result | 150 |
peripheral blood | 150 |
food allergy | 149 |
stem cell | 149 |
side effects | 147 |
viral load | 147 |
blood product | 146 |
results findings | 144 |
general population | 142 |
clinical practice | 141 |
positive test | 141 |
bacterial contamination | 139 |
chain reaction | 138 |
design methods | 138 |
first time | 137 |
present study | 137 |
clinically significant | 136 |
positive samples | 135 |
clinical trials | 135 |
tested positive | 135 |
polymerase chain | 135 |
diagnostic accuracy | 130 |
cd cd | 130 |
blood services | 129 |
coronavirus disease | 129 |
lg ml | 129 |
transfusion services | 128 |
blood safety | 128 |
year old | 127 |
rbc units | 127 |
clinical signs | 126 |
age group | 122 |
hbv dna | 121 |
blood component | 120 |
commercially available | 120 |
false positive | 120 |
results suggest | 119 |
antibody screening | 118 |
national blood | 117 |
intensive care | 116 |
university hospital | 115 |
specific antibodies | 115 |
autologous blood | 114 |
antiglobulin test | 113 |
body weight | 113 |
room temperature | 113 |
doc id | 112 |
blood pressure | 112 |
may also | 112 |
cord uid | 112 |
gene expression | 110 |
adverse reactions | 110 |
group testing | 110 |
mass spectrometry | 109 |
diagnostic test | 109 |
grass pollen | 109 |
blood centers | 106 |
immune response | 105 |
false negative | 105 |
age groups | 105 |
per year | 104 |
statistical analysis | 104 |
significantly lower | 104 |
time series | 104 |
staphylococcus aureus | 104 |
positive tests | 103 |
acute respiratory | 103 |
positive rate | 103 |
patients undergoing | 102 |
rbc transfusion | 102 |
blood loss | 102 |
cd cells | 102 |
blood culture | 102 |
systematic review | 102 |
patient care | 102 |
medical center | 101 |
blood service | 101 |
frozen plasma | 101 |
donor selection | 100 |
study period | 99 |
total ige | 98 |
respiratory tract | 97 |
significantly increased | 97 |
informed consent | 96 |
screening test | 96 |
last years | 96 |
amino acid | 95 |
risk factor | 95 |
tests performed | 95 |
negative results | 94 |
allergic reactions | 94 |
cuff leak | 94 |
red cross | 93 |
atopic dermatitis | 93 |
fresh frozen | 93 |
laboratory tests | 93 |
prick test | 93 |
median age | 92 |
novel coronavirus | 92 |
allergic patients | 92 |
platelet transfusion | 92 |
significantly different | 91 |
gold standard | 91 |
antibody tests | 91 |
results show | 90 |
blood groups | 90 |
time pcr | 90 |
diagnostic testing | 90 |
blood volume | 90 |
stem cells | 89 |
serological tests | 89 |
two different | 89 |
increased risk | 88 |
house dust | 88 |
adverse effects | 88 |
predictive value | 88 |
determine whether | 88 |
per day | 88 |
significant increase | 88 |
transfusion practice | 87 |
one patient | 87 |
western blot | 87 |
commonly used | 87 |
serum samples | 86 |
sickle cell | 86 |
primary care | 86 |
antibody screen | 85 |
hcv rna | 85 |
prick tests | 84 |
nucleic acids | 84 |
leak test | 84 |
one year | 84 |
large number | 83 |
within hours | 83 |
patients received | 83 |
cell line | 82 |
cell lines | 82 |
significantly reduced | 82 |
world health | 82 |
logistic regression | 82 |
cardiac surgery | 82 |
positive cases | 81 |
plasma samples | 81 |
cord blood | 81 |
results indicate | 80 |
time donors | 80 |
transfusion therapy | 80 |
social distancing | 80 |
ige levels | 80 |
factor viii | 80 |
emergency department | 79 |
quality assurance | 79 |
group system | 79 |
contact tracing | 79 |
cfu ml | 79 |
transfusion reaction | 78 |
patients receiving | 78 |
dust mite | 78 |
clinically relevant | 78 |
donate blood | 77 |
female donors | 77 |
patients treated | 77 |
monoclonal antibodies | 77 |
retrospective study | 77 |
high risk | 77 |
old female | 77 |
care unit | 76 |
massive transfusion | 76 |
data suggest | 76 |
antibody test | 76 |
positive result | 76 |
recent years | 76 |
reference laboratory | 76 |
test performance | 76 |
heart failure | 76 |
sample preparation | 75 |
disease control | 75 |
health organization | 74 |
well tolerated | 74 |
blood sample | 74 |
buffy coat | 73 |
new york | 73 |
safe blood | 73 |
voluntary blood | 73 |
high prevalence | 73 |
blood cultures | 73 |
direct antiglobulin | 72 |
important role | 72 |
class i | 72 |
old male | 72 |
immune system | 72 |
skin tests | 72 |
iron deficiency | 72 |
blood banking | 72 |
critically ill | 71 |
antibody identification | 71 |
hemolytic transfusion | 71 |
antibody testing | 71 |
see table | 71 |
highly sensitive | 70 |
monoclonal antibody | 70 |
sample size | 70 |
type i | 70 |
respiratory syndrome | 69 |
analyzed using | 69 |
real time | 69 |
two patients | 69 |
clinical laboratory | 69 |
rapid test | 68 |
results obtained | 68 |
rhd gene | 68 |
white blood | 68 |
standard deviation | 67 |
previous studies | 67 |
laboratory testing | 67 |
flow assays | 67 |
physical examination | 67 |
statistical significance | 67 |
flow assay | 67 |
widely used | 67 |
clinical microbiology | 66 |
hematopoietic stem | 66 |
pathogen inactivation | 66 |
genomic dna | 66 |
reference standard | 65 |
per patient | 65 |
clinical laboratories | 65 |
even though | 65 |
oxidative stress | 65 |
mcg ml | 65 |
blood transfusions | 65 |
year period | 65 |
two years | 65 |
regression analysis | 65 |
clinical trial | 65 |
pathogen reduction | 64 |
retrospective analysis | 64 |
adult patients | 64 |
results showed | 64 |
patient samples | 64 |
skin test | 64 |
measured using | 63 |
additive solution | 63 |
donor screening | 63 |
rapid diagnostic | 63 |
respiratory viruses | 63 |
buffy coats | 62 |
olfactory function | 62 |
test positive | 62 |
clinical symptoms | 62 |
spinal cord | 62 |
per unit | 62 |
medical records | 62 |
severe acute | 61 |
bact alert | 61 |
platelet products | 61 |
rhce ce | 61 |
pediatric patients | 61 |
test rate | 60 |
infection rate | 60 |
platelet counts | 60 |
acid amplification | 60 |
small number | 60 |
cell count | 60 |
ferritin levels | 60 |
antigen expression | 60 |
skin testing | 60 |
indirect antiglobulin | 60 |
high sensitivity | 59 |
fully automated | 59 |
broad spectrum | 59 |
may lead | 59 |
cell disease | 59 |
confirmed cases | 58 |
nasal spray | 58 |
general hospital | 58 |
abo blood | 58 |
transfusion safety | 58 |
may cause | 58 |
first step | 58 |
attack rate | 58 |
monoclonal anti | 58 |
tested using | 57 |
acceleration index | 57 |
negative test | 57 |
pcr test | 57 |
high frequency | 57 |
apheresis platelets | 57 |
respiratory rate | 57 |
nursing home | 57 |
plasma units | 57 |
positive blood | 57 |
cell culture | 56 |
family history | 56 |
pilot study | 56 |
trauma patients | 56 |
per test | 56 |
molecular testing | 56 |
cohort study | 56 |
storage time | 56 |
systematic reviews | 56 |
platelet function | 55 |
significant reduction | 55 |
hbv infection | 55 |
high level | 55 |
confidence interval | 55 |
two weeks | 55 |
regional blood | 55 |
ill patients | 55 |
hb level | 55 |
primary case | 55 |
asthma symptoms | 55 |
blood type | 55 |
column agglutination | 55 |
mrna expression | 55 |
hemolytic anemia | 55 |
allergic diseases | 55 |
hla antibodies | 55 |
endothelial cells | 55 |
determined using | 54 |
rapid tests | 54 |
scansystem tm | 54 |
hospitalized patients | 54 |
laboratory test | 54 |
posted june | 54 |
significantly decreased | 54 |
transfused patients | 54 |
test methods | 54 |
quality management | 54 |
infection control | 54 |
posted september | 54 |
evaluated using | 54 |
false positives | 54 |
vitro activity | 54 |
ml kg | 54 |
asthma control | 54 |
drug administration | 54 |
platelets stored | 53 |
viral infections | 53 |
among patients | 53 |
growth factor | 53 |
repeat donors | 53 |
serological testing | 53 |
three months | 53 |
confirmed positive | 53 |
study showed | 53 |
time points | 53 |
abstract withdrawn | 53 |
samples collected | 53 |
blood management | 53 |
negative blood | 53 |
within days | 52 |
blood count | 52 |
wide range | 52 |
sample collection | 52 |
urinary tract | 52 |
abo rh | 52 |
reverse transcription | 52 |
antigen detection | 52 |
one case | 52 |
old woman | 52 |
ex vivo | 52 |
severe asthma | 52 |
tract infections | 51 |
currently available | 51 |
positive dat | 51 |
specific igg | 51 |
information system | 51 |
trima accel | 51 |
healthy dogs | 51 |
airway obstruction | 51 |
prospective study | 51 |
fetal dna | 51 |
plasma exchange | 51 |
transfusion transmitted | 51 |
adverse reaction | 51 |
signal amplification | 51 |
positive control | 51 |
findings suggest | 50 |
male donors | 50 |
patient population | 50 |
epithelial cells | 50 |
significantly associated | 50 |
per month | 50 |
lung injury | 50 |
hearing loss | 50 |
test accuracy | 50 |
testing capacity | 50 |
also observed | 50 |
hospital transfusion | 50 |
may help | 50 |
plt count | 50 |
type ii | 50 |
high dose | 50 |
allergic asthma | 50 |
storage period | 50 |
cell concentrates | 50 |
performance characteristics | 50 |
dna damage | 50 |
infected individuals | 49 |
complete blood | 49 |
blood centre | 49 |
month period | 49 |
healthy volunteers | 49 |
airway inflammation | 49 |
three years | 49 |
mouse model | 49 |
cell transplantation | 49 |
abdominal pain | 49 |
healthy donors | 49 |
may occur | 49 |
pcr testing | 49 |
analysis showed | 49 |
donated blood | 49 |
nervous system | 49 |
transmitted infections | 49 |
generation sequencing | 49 |
lung function | 48 |
reactive protein | 48 |
treated cells | 48 |
samples tested | 48 |
table shows | 48 |
clinical studies | 48 |
higher risk | 48 |
treated rbcs | 48 |
turnaround time | 48 |
cell death | 48 |
dendritic cells | 48 |
adverse event | 48 |
blood system | 48 |
mast cell | 48 |
patients without | 48 |
previously reported | 48 |
virus infection | 48 |
igg antibodies | 48 |
donor samples | 48 |
positive antibody | 48 |
blood establishments | 48 |
low hb | 48 |
medical history | 48 |
six months | 48 |
units per | 48 |
respiratory symptoms | 48 |
bronchial asthma | 48 |
flow cytometric | 48 |
hemolytic disease | 48 |
gel test | 47 |
therapeutic plasma | 47 |
three patients | 47 |
preliminary results | 47 |
patient blood | 47 |
cell transfusion | 47 |
positivity rate | 47 |
rhd genotyping | 47 |
gene therapy | 47 |
molecular weight | 47 |
allogeneic blood | 47 |
days post | 47 |
pool size | 47 |
high throughput | 47 |
family members | 47 |
food allergens | 47 |
linear regression | 47 |
viral rna | 47 |
donor blood | 47 |
rhd negative | 47 |
disease severity | 47 |
antimicrobial agents | 47 |
heart rate | 46 |
long term | 46 |
years ago | 46 |
group antigens | 46 |
donor population | 46 |
allergic reaction | 46 |
rbc transfusions | 46 |
pcr tests | 46 |
post transfusion | 46 |
fatality rate | 46 |
bacterial growth | 46 |
ms ms | 46 |
solid phase | 46 |
center background | 46 |
susceptibility testing | 46 |
escherichia coli | 46 |
risk assessment | 46 |
cell cultures | 46 |
cell units | 46 |
rapid detection | 46 |
amino acids | 46 |
birth weight | 45 |
next generation | 45 |
reported cases | 45 |
healthcare system | 45 |
study group | 45 |
low levels | 45 |
three different | 45 |
clinical isolates | 45 |
true positive | 45 |
test probability | 45 |
analysis using | 45 |
first case | 45 |
study included | 45 |
breast cancer | 45 |
significant antibodies | 45 |
platelet units | 45 |
one week | 45 |
care testing | 45 |
apheresis platelet | 45 |
test food | 45 |
persistent asthma | 45 |
accuracy studies | 45 |
assessed using | 45 |
positive donations | 45 |
healthy individuals | 45 |
positive patients | 44 |
multiple sclerosis | 44 |
resource settings | 44 |
liquid chromatography | 44 |
single donor | 44 |
patient safety | 44 |
different countries | 44 |
data analysis | 44 |
time period | 44 |
also found | 44 |
patient outcomes | 44 |
influenza virus | 44 |
upper bound | 44 |
significant decrease | 44 |
negative control | 44 |
antibody detection | 44 |
platelet pools | 44 |
confidence intervals | 44 |
controlled trial | 44 |
nursing homes | 43 |
positive cells | 43 |
data collection | 43 |
platelet aggregation | 43 |
positive donors | 43 |
within minutes | 43 |
study aimed | 43 |
negative result | 43 |
blood glucose | 43 |
health authorities | 43 |
different types | 43 |
one study | 43 |
th day | 43 |
packed red | 43 |
iron depletion | 43 |
placebo group | 43 |
testing methods | 43 |
analysis revealed | 43 |
isothermal amplification | 43 |
pollen season | 42 |
medical record | 42 |
average number | 42 |
food allergies | 42 |
serum ige | 42 |
serious adverse | 42 |
tested negative | 42 |
platelet storage | 42 |
also performed | 42 |
will also | 42 |
clinical outcomes | 42 |
blood grouping | 42 |
respiratory infections | 42 |
cell surface | 42 |
high levels | 42 |
multiplex pcr | 42 |
effective treatment | 42 |
quality system | 42 |
respiratory virus | 42 |
patient received | 42 |
asymptomatic individuals | 42 |
blood screening | 42 |
tests per | 42 |
terumo bct | 42 |
microbiology laboratory | 42 |
clinical outcome | 42 |
rich plasma | 42 |
significant changes | 42 |
high incidence | 41 |
cd expression | 41 |
response rate | 41 |
significant correlation | 41 |
immunosorbent assay | 41 |
heart disease | 41 |
study population | 41 |
platelet yield | 41 |
molecular diagnostics | 41 |
clinical use | 41 |
high quality | 41 |
serum levels | 41 |
european countries | 41 |
significant improvement | 41 |
clinical data | 41 |
renal failure | 41 |
peanut allergy | 41 |
based testing | 41 |
platelet concentrate | 41 |
acid testing | 40 |
iron stores | 40 |
hbc positive | 40 |
relatively low | 40 |
chest ct | 40 |
vital signs | 40 |
clinical performance | 40 |
diabetes mellitus | 40 |
platelet transfusions | 40 |
identifi cation | 40 |
cell proliferation | 40 |
sir model | 40 |
birch pollen | 40 |
healthy controls | 40 |
routine use | 40 |
blood flow | 40 |
normal range | 40 |
secondary cases | 40 |
molecular methods | 40 |
gamma globulin | 40 |
ionlast tm | 39 |
united kingdom | 39 |
serum ferritin | 39 |
related symptoms | 39 |
cd cell | 39 |
chronic urticaria | 39 |
anti hpa | 39 |
mg day | 39 |
clinical history | 39 |
iron supplementation | 39 |
antibody responses | 39 |
wild type | 39 |
five patients | 39 |
among blood | 39 |
observational study | 39 |
clinical relevance | 39 |
tertiary care | 39 |
molecular techniques | 39 |
hla class | 39 |
using two | 39 |
nasal congestion | 39 |
hb levels | 39 |
syndrome coronavirus | 39 |
confirmatory testing | 39 |
tissue culture | 39 |
testing strategy | 39 |
days later | 39 |
plasma concentrations | 39 |
well known | 39 |
positive skin | 39 |
may provide | 39 |
resistant strains | 39 |
platelet antigens | 39 |
expression levels | 39 |
old man | 38 |
treatment groups | 38 |
respiratory distress | 38 |
transfusion center | 38 |
income countries | 38 |
bacterial screening | 38 |
positive predictive | 38 |
transfusion practices | 38 |
extubation airway | 38 |
bacterial infections | 38 |
function tests | 38 |
healthy subjects | 38 |
negative controls | 38 |
previously described | 38 |
respiratory disease | 38 |
protein expression | 38 |
linked immunosorbent | 38 |
cell antigens | 38 |
donor recruitment | 38 |
management system | 38 |
decision making | 38 |
ct scan | 38 |
results demonstrate | 38 |
posted may | 38 |
rights reserved | 38 |
times higher | 38 |
testing using | 38 |
mononuclear cells | 38 |
inclusion criteria | 38 |
machine learning | 38 |
incubation period | 37 |
patients showed | 37 |
time blood | 37 |
young children | 37 |
i ii | 37 |
lower bound | 37 |
general practitioners | 37 |
severe thrombocytopenia | 37 |
surface antigen | 37 |
milk allergy | 37 |
cancer patients | 37 |
much higher | 37 |
increased significantly | 37 |
higher prevalence | 37 |
test sensitivity | 37 |
negative predictive | 37 |
gel electrophoresis | 37 |
ige level | 37 |
molecular diagnostic | 37 |
pcr assay | 37 |
study shows | 37 |
cobe spectra | 37 |
single nucleotide | 37 |
clinical characteristics | 37 |
hospital blood | 37 |
window period | 37 |
care tests | 37 |
urine samples | 37 |
total protein | 37 |
mean value | 37 |
platelet quality | 37 |
clinical course | 37 |
one day | 37 |
extremely rare | 37 |
compatible blood | 37 |
enzyme treated | 37 |
clinical features | 36 |
taken together | 36 |
platelet concentration | 36 |
left ventricular | 36 |
healthcare workers | 36 |
multiple myeloma | 36 |
control subjects | 36 |
fecal samples | 36 |
factors associated | 36 |
past years | 36 |
months later | 36 |
data points | 36 |
american red | 36 |
low level | 36 |
per week | 36 |
large numbers | 36 |
pulmonary edema | 36 |
antimicrobial resistance | 36 |
shelf life | 36 |
cell viability | 36 |
bacterial detection | 36 |
serum albumin | 36 |
healthcare professionals | 36 |
health laboratories | 36 |
cell separator | 36 |
quality assessment | 36 |
days prior | 36 |
fold increase | 36 |
information security | 36 |
improve patient | 36 |
apheresis procedures | 36 |
zika virus | 36 |
randomly selected | 36 |
severe disease | 36 |
clinical significance | 36 |
nitric oxide | 36 |
data collected | 36 |
alloimmune thrombocytopenia | 36 |
symptomatic patients | 36 |
cell types | 36 |
testing positive | 36 |
tm platelet | 36 |
platelet kit | 36 |
patient management | 36 |
differential diagnosis | 36 |
upper respiratory | 35 |
significant effect | 35 |
clinical presentation | 35 |
three times | 35 |
haemolytic disease | 35 |
dust mites | 35 |
take place | 35 |
infected samples | 35 |
provocation test | 35 |
rhd positive | 35 |
transfusion associated | 35 |
two samples | 35 |
several studies | 35 |
health system | 35 |
reproduction number | 35 |
time point | 35 |
body mass | 35 |
screening tests | 35 |
detection limit | 35 |
serum concentrations | 35 |
internal medicine | 35 |
may play | 35 |
immune responses | 35 |
three days | 35 |
one month | 35 |
asthmatic patients | 35 |
four patients | 35 |
future studies | 35 |
high specificity | 35 |
laboratory data | 35 |
high titer | 35 |
included patients | 35 |
igg levels | 35 |
mobile phone | 35 |
transfusion recipients | 35 |
antibiotic therapy | 35 |
preliminary data | 35 |
molecular recognition | 34 |
magnetic resonance | 34 |
hiv infection | 34 |
treated patients | 34 |
new cases | 34 |
five years | 34 |
clinical setting | 34 |
new donors | 34 |
may result | 34 |
viral loads | 34 |
viral hepatitis | 34 |
coagulation factors | 34 |
three groups | 34 |
infected patients | 34 |
specific antibody | 34 |
naturally occurring | 34 |
asthma severity | 34 |
posted october | 34 |
broth microdilution | 34 |
also tested | 34 |
magnetic nanoparticles | 34 |
different blood | 34 |
mean hb | 34 |
residual risk | 34 |
patients suffering | 34 |
retrospective review | 34 |
clinical samples | 34 |
specific immunotherapy | 34 |
dna samples | 34 |
seasonal allergic | 34 |
negative bacteria | 33 |
potential risk | 33 |
electronic medical | 33 |
ml min | 33 |
lung cancer | 33 |
treatment period | 33 |
routine blood | 33 |
hypersensitivity reactions | 33 |
viral inactivation | 33 |
hiv positive | 33 |
medical care | 33 |
transfusion related | 33 |
low prevalence | 33 |
ige binding | 33 |
limited settings | 33 |
young people | 33 |
positive correlation | 33 |
many patients | 33 |
scd patients | 33 |
cell activation | 33 |
cost per | 33 |
mast cells | 33 |
weight loss | 33 |
group systems | 33 |
working group | 33 |
genetic testing | 33 |
positive reactions | 33 |
mean platelet | 33 |
cerebrospinal fluid | 33 |
reagent lots | 33 |
performed according | 33 |
sanger sequencing | 33 |
normal rhd | 33 |
hours post | 32 |
several years | 32 |
human plasma | 32 |
neonatal alloimmune | 32 |
case reports | 32 |
randomized controlled | 32 |
arachidonic acid | 32 |
intravenous immunoglobulin | 32 |
primary cases | 32 |
poc tests | 32 |
control study | 32 |
egg white | 32 |
last two | 32 |
blood tests | 32 |
vitro quality | 32 |
infectious agents | 32 |
blood collected | 32 |
chart review | 32 |
fatty acid | 32 |
analytical sensitivity | 32 |
donating blood | 32 |
regular blood | 32 |
molecular tests | 32 |
current study | 32 |
least two | 32 |
corrective actions | 32 |
central laboratory | 32 |
standard operating | 32 |
gram negative | 32 |
nan doi | 32 |
will need | 32 |
vast majority | 31 |
may contribute | 31 |
patients may | 31 |
last months | 31 |
chronic disease | 31 |
two cases | 31 |
liver disease | 31 |
hcv infection | 31 |
respiratory syncytial | 31 |
potential secondary | 31 |
considered significant | 31 |
transplant recipients | 31 |
time spent | 31 |
specific primers | 31 |
control samples | 31 |
significantly improved | 31 |
tract infection | 31 |
four different | 31 |
previously tested | 31 |
surgical procedures | 31 |
dct methods | 31 |
low risk | 31 |
operating procedures | 31 |
reported infections | 31 |
large volume | 31 |
national health | 31 |
treatment group | 31 |
symptom score | 31 |
new technology | 31 |
sectional study | 31 |
piperacillin tazobactam | 31 |
case study | 31 |
host disease | 31 |
deferred donors | 31 |
myocardial infarction | 31 |
similar results | 31 |
selection criteria | 31 |
clinical efficacy | 31 |
index test | 31 |
kg day | 31 |
tests may | 31 |
febrile illness | 31 |
donor base | 31 |
blood bags | 31 |
based assays | 31 |
will help | 31 |
clinical diagnosis | 31 |
antimicrobial susceptibility | 31 |
recent studies | 31 |
tube method | 31 |
data indicate | 31 |
clinical improvement | 30 |
acid test | 30 |
rapid antigen | 30 |
antiviral drugs | 30 |
olfactory dysfunction | 30 |
agglutination technology | 30 |
risk reduction | 30 |
medical treatment | 30 |
mayo clinic | 30 |
reagent red | 30 |
first two | 30 |
quality improvement | 30 |
czech republic | 30 |
mechanical ventilation | 30 |
nasopharyngeal swab | 30 |
molecular mechanisms | 30 |
eight patients | 30 |
likelihood ratios | 30 |
physical exam | 30 |
will allow | 30 |
medication use | 30 |
standard methods | 30 |
patient developed | 30 |
transfusion protocol | 30 |
may affect | 30 |
medical staff | 30 |
related complications | 30 |
lower risk | 30 |
two months | 30 |
healthy control | 30 |
two days | 30 |
dna sequencing | 30 |
blood derived | 29 |
pseudomonas aeruginosa | 29 |
antigen test | 29 |
growth factors | 29 |
allergic disease | 29 |
common cause | 29 |
transfusion vol | 29 |
many cases | 29 |
abo typing | 29 |
low sensitivity | 29 |
igm antibodies | 29 |
testing rates | 29 |
immune cells | 29 |
transmission risk | 29 |
data show | 29 |
time consuming | 29 |
utilization management | 29 |
syncytial virus | 29 |
population prevalence | 29 |
developing world | 29 |
pollen allergy | 29 |
children aged | 29 |
regular donors | 29 |
control groups | 29 |
contact dermatitis | 29 |
human immunodeficiency | 29 |
five days | 29 |
female patient | 29 |
interquartile range | 29 |
average age | 29 |
antibody titers | 29 |
pulmonary disease | 29 |
pcr amplification | 29 |
odds ratio | 29 |
surgery patients | 29 |
circulatory overload | 29 |
normal dogs | 29 |
negative samples | 29 |
based tests | 29 |
care workers | 29 |
asthma exacerbation | 29 |
will require | 29 |
units transfused | 29 |
study demonstrated | 29 |
diagnostic tools | 29 |
many countries | 29 |
probably due | 29 |
automated blood | 29 |
rbc antigens | 29 |
hemoglobin levels | 29 |
one unit | 29 |
done using | 29 |
drug allergy | 29 |
allergic symptoms | 29 |
symptom onset | 29 |
nasal polyps | 29 |
copies ml | 29 |
clinical impact | 29 |
one test | 29 |
detection methods | 29 |
control dogs | 28 |
data obtained | 28 |
mycobacterium tuberculosis | 28 |
exclusion criteria | 28 |
platelet components | 28 |
published data | 28 |
nat screening | 28 |
controlled study | 28 |
group size | 28 |
pharmaceutical preparations | 28 |
study suggests | 28 |
antibiotic resistance | 28 |
close contact | 28 |
lupus erythematosus | 28 |
transfusion policy | 28 |
plasma volume | 28 |
acute lung | 28 |
may require | 28 |
test rates | 28 |
rare blood | 28 |
food materials | 28 |
pregnant woman | 28 |
post mortem | 28 |
rhd typing | 28 |
significantly greater | 28 |
dependent manner | 28 |
clinical settings | 28 |
south korea | 28 |
investigate whether | 28 |
body condition | 28 |
based bct | 28 |
male patient | 28 |
routinely used | 28 |
teaching hospital | 28 |
clinical specimens | 28 |
negative tests | 28 |
molecular assays | 28 |
serologic testing | 28 |
calculated using | 28 |
volume reduction | 28 |
using flow | 28 |
single dose | 28 |
bleeding patients | 28 |
ethnic groups | 28 |
per rbc | 28 |
one sample | 28 |
ml per | 28 |
median time | 28 |
across different | 28 |
health services | 28 |
manual tube | 28 |
russian federation | 28 |
mediated isothermal | 28 |
tests positive | 28 |
relatively high | 27 |
global health | 27 |
soft tissue | 27 |
mortality rate | 27 |
repeat blood | 27 |
supply chain | 27 |
pretransfusion testing | 27 |
genetic material | 27 |
gold nanoparticles | 27 |
seven days | 27 |
prevalence among | 27 |
rhd exons | 27 |
differ significantly | 27 |
gastrointestinal disease | 27 |
aged years | 27 |
different methods | 27 |
central nervous | 27 |
minute ventilation | 27 |
positive controls | 27 |
hemoglobin level | 27 |
nasal symptoms | 27 |
mean ae | 27 |
clinical sensitivity | 27 |
resistant staphylococcus | 27 |
ige reactivity | 27 |
post irradiation | 27 |
test utilization | 27 |
human serum | 27 |
square test | 27 |
two methods | 27 |
seroconversion panels | 27 |
plasma transfusion | 27 |
one hour | 27 |
patch test | 27 |
repeated measures | 27 |
large scale | 27 |
care system | 27 |
emergency use | 27 |
plasma derivates | 27 |
studies using | 27 |
patients aged | 27 |
screening testing | 27 |
one single | 27 |
pcr assays | 27 |
phase ii | 27 |
asymptomatic patients | 27 |
positive reaction | 27 |
cell separators | 27 |
within normal | 27 |
common causes | 27 |
test method | 27 |
lactate dehydrogenase | 27 |
health insurance | 27 |
replacement therapy | 27 |
lymph nodes | 27 |
inflammatory cytokines | 27 |
autoimmune hemolytic | 27 |
mean number | 27 |
random variable | 27 |
hpa antibodies | 27 |
rare donor | 27 |
bacterial culture | 27 |
national guidelines | 27 |
repeat testing | 27 |
vitro studies | 26 |
single unit | 26 |
posted november | 26 |
htlv i | 26 |
asthma patients | 26 |
group antigen | 26 |
low frequency | 26 |
testing strategies | 26 |
smooth muscle | 26 |
inventory management | 26 |
enzyme immunoassay | 26 |
national institute | 26 |
immunodeficiency virus | 26 |
negative rate | 26 |
laboratory results | 26 |
nccls guidelines | 26 |
across countries | 26 |
testing rate | 26 |
platelet refractoriness | 26 |
maternal plasma | 26 |
limited number | 26 |
results will | 26 |
drug resistance | 26 |
see sect | 26 |
cell antibodies | 26 |
clinical evaluation | 26 |
smell function | 26 |
health problem | 26 |
weeks later | 26 |
molecules per | 26 |
transfusion testing | 26 |
based methods | 26 |
less frequent | 26 |
spectra optia | 26 |
computed tomography | 26 |
cost effective | 26 |
study evaluated | 26 |
much lower | 26 |
frequently used | 26 |
platelet additive | 26 |
cell free | 26 |
screening assays | 26 |
clinical response | 26 |
compared using | 26 |
venous blood | 26 |
significant impact | 26 |
donor deferral | 26 |
anaphylactic reaction | 26 |
patients will | 26 |
old caucasian | 26 |
patients admitted | 26 |
european union | 26 |
decreased significantly | 26 |
worst case | 26 |
mg bid | 26 |
allergen immunotherapy | 26 |
average acuity | 26 |
sensorineural hearing | 26 |
affected dogs | 26 |
using different | 26 |
consecutive days | 26 |
irradiated blood | 26 |
developing countries | 26 |
statistical difference | 26 |
life threatening | 26 |
blood establishment | 26 |
drug development | 26 |
early stages | 26 |
transcription factor | 26 |
vestibular function | 26 |
study aims | 26 |
random variables | 26 |
lower bounds | 26 |
comparative study | 26 |
samples obtained | 26 |
storage lesion | 25 |
twice daily | 25 |
white cell | 25 |
pulmonary function | 25 |
animal model | 25 |
analysed using | 25 |
compatibility testing | 25 |
diagnostic sensitivity | 25 |
low dose | 25 |
representative testing | 25 |
policy makers | 25 |
control measures | 25 |
also included | 25 |
raw data | 25 |
controlled trials | 25 |
may represent | 25 |
lymph node | 25 |
one hundred | 25 |
major challenge | 25 |
antibody response | 25 |
reverse transcriptase | 25 |
platelet content | 25 |
age years | 25 |
false negatives | 25 |
posted august | 25 |
specimen collection | 25 |
test system | 25 |
cells mm | 25 |
safety profile | 25 |
sexually transmitted | 25 |
viral infection | 25 |
patients underwent | 25 |
well established | 25 |
inhaled corticosteroids | 25 |
flow cytometer | 25 |
component therapy | 25 |
collected using | 25 |
less likely | 25 |
apheresis donors | 25 |
reactive samples | 25 |
severe allergic | 25 |
higher levels | 25 |
antigen tests | 25 |
gel cards | 25 |
clinical care | 25 |
limited data | 25 |
reference range | 25 |
internal control | 25 |
eosinophil count | 25 |
data management | 25 |
new automated | 25 |
rapid diagnosis | 25 |
short period | 25 |
appropriate use | 25 |
south africa | 25 |
new blood | 25 |
chlamydia trachomatis | 25 |
celiac disease | 25 |
sequence analysis | 25 |
weeks gestation | 25 |
helicobacter pylori | 25 |
automated system | 25 |
mic mic | 25 |
research software | 25 |
animal models | 25 |
cross blood | 25 |
herd immunity | 25 |
lower levels | 25 |
intercept blood | 25 |
white matter | 25 |
exact test | 25 |
antibiotic treatment | 25 |
information regarding | 25 |
may serve | 24 |
recognition elements | 24 |
patient identification | 24 |
every day | 24 |
pall ebds | 24 |
exercise test | 24 |
rbc unit | 24 |
hospital admission | 24 |
north america | 24 |
azelastine nasal | 24 |
hospital stay | 24 |
plasmodium falciparum | 24 |
also used | 24 |
poisson subset | 24 |
cell wall | 24 |
external quality | 24 |
often used | 24 |
asthma medication | 24 |
patients presented | 24 |
rabies virus | 24 |
dose response | 24 |
six patients | 24 |
relative risk | 24 |
asthmatic children | 24 |
high resolution | 24 |
fatty acids | 24 |
will provide | 24 |
surface area | 24 |
ultrio assay | 24 |
transfusion centers | 24 |
patient populations | 24 |
donor return | 24 |
plasma fractionation | 24 |
pollen allergens | 24 |
wound healing | 24 |
viral particles | 24 |
test negative | 24 |
abo group | 24 |
insulin resistance | 24 |
fibrin glue | 24 |
cell counts | 24 |
normal saline | 24 |
clinical decision | 24 |
reference laboratories | 24 |
rh typing | 24 |
detection system | 24 |
silver nanoparticles | 24 |
significant association | 24 |
antibody titer | 24 |
total blood | 24 |
studies showed | 24 |
donor center | 24 |
way anova | 24 |
included studies | 24 |
suspected cases | 24 |
enveloped viruses | 24 |
last year | 24 |
using commercial | 24 |
clinical manifestations | 24 |
thalassemic patients | 24 |
sample volume | 24 |
standard serological | 24 |
respiratory pathogens | 24 |
fatality rates | 24 |
electron microscopy | 24 |
pooled platelet | 24 |
testing data | 24 |
donor cells | 23 |
first months | 23 |
mg daily | 23 |
mean time | 23 |
diagnostic assays | 23 |
early detection | 23 |
two units | 23 |
based transfusion | 23 |
university school | 23 |
routine testing | 23 |
magnetic beads | 23 |
standard deviations | 23 |
chronic rhinosinusitis | 23 |
low molecular | 23 |
better understand | 23 |
congestive heart | 23 |
left atrial | 23 |
second wave | 23 |
cardiac diseases | 23 |
veterinary medicine | 23 |
transfusion history | 23 |
graphical displays | 23 |
upsit scores | 23 |
inhibitory concentration | 23 |
two types | 23 |
may vary | 23 |
respiratory viral | 23 |
laboratory diagnosis | 23 |
anaphylactic reactions | 23 |
stored platelets | 23 |
erythrocyte antibodies | 23 |
random sample | 23 |
cde cde | 23 |
cell adhesion | 23 |
kg body | 23 |
high affinity | 23 |
cells ml | 23 |
based detection | 23 |
solid tumors | 23 |
laboratory parameters | 23 |
also showed | 23 |
phase i | 23 |
related acute | 23 |
respiratory diseases | 23 |
ten years | 23 |
rhd beadchip | 23 |
patient presented | 23 |
major allergen | 23 |
frequency antigens | 23 |
deficient mice | 23 |
magnetic field | 23 |
health status | 23 |
first report | 23 |
final product | 23 |
significance level | 23 |
free fetal | 23 |
iron overload | 23 |
hours later | 23 |
kidney disease | 23 |
delayed hemolytic | 23 |
challenge test | 23 |
deferral rates | 23 |
allergen challenge | 23 |
storage conditions | 23 |
among others | 23 |
well documented | 23 |
less sensitive | 23 |
age range | 23 |
monte carlo | 23 |
laboratory findings | 23 |
cost savings | 23 |
endemic areas | 23 |
rhinitis symptoms | 23 |
fda approval | 23 |
ige mediated | 23 |
connective tissue | 23 |
transmissible infections | 23 |
regression models | 23 |
streptococcus pneumoniae | 23 |
screening program | 23 |
human platelet | 23 |
detection tests | 23 |
early stage | 23 |
blood specimens | 23 |
component preparation | 23 |
exchange transfusion | 23 |
chronic hepatitis | 23 |
method using | 23 |
group ab | 23 |
studies will | 23 |
critical care | 23 |
cell yield | 23 |
allogenic blood | 23 |
saharan africa | 22 |
blot analysis | 22 |
clinical utility | 22 |
testing results | 22 |
healthy adult | 22 |
protective measures | 22 |
umbilical cord | 22 |
high rate | 22 |
tree pollen | 22 |
neonatal intensive | 22 |
ml vs | 22 |
showed significant | 22 |
cell migration | 22 |
cold storage | 22 |
systemic lupus | 22 |
primary endpoint | 22 |
first study | 22 |
million people | 22 |
related adverse | 22 |
quantum dots | 22 |
allows us | 22 |
tandem mass | 22 |
corticosteroid therapy | 22 |
single test | 22 |
serum tt | 22 |
study demonstrates | 22 |
hcv antibodies | 22 |
herpes simplex | 22 |
hb content | 22 |
laser desorption | 22 |
nine patients | 22 |
mental health | 22 |
results may | 22 |
fda approved | 22 |
thrombin generation | 22 |
gastric cancer | 22 |
plasma levels | 22 |
urgent need | 22 |
rh phenotype | 22 |
population level | 22 |
rhd weak | 22 |
emergency room | 22 |
compatible platelets | 22 |
higher number | 22 |
caucasian population | 22 |
practice guidelines | 22 |
wbc count | 22 |
reactive results | 22 |
early diagnosis | 22 |
class ii | 22 |
expressing cells | 22 |
active metabolite | 22 |
coagulation factor | 22 |
excessive bleeding | 22 |
individual patient | 22 |
serum total | 22 |
marrow transplantation | 22 |
vasovagal reactions | 22 |
causative agent | 22 |
also positive | 22 |
antibody positive | 22 |
motor neuron | 22 |
nasal obstruction | 22 |
african american | 22 |
first week | 22 |
investigated whether | 22 |
previously published | 22 |
neutralizing antibodies | 22 |
donor deferrals | 22 |
gram positive | 22 |
drug allergies | 22 |
based lateral | 22 |
academic medical | 22 |
widely available | 22 |
donor safety | 22 |
relative error | 22 |
developed countries | 22 |
chronic inflammation | 22 |
published studies | 22 |
renal function | 22 |
process control | 22 |
case fatality | 22 |
care providers | 22 |
positive impact | 22 |
surgical patients | 22 |
distancing measures | 22 |
clinical suspicion | 22 |
severe symptoms | 22 |
complement activation | 22 |
positive direct | 22 |
cd count | 22 |
plasma products | 22 |
haemolytic anaemia | 22 |
colorectal cancer | 22 |
increasing number | 22 |
enzyme activity | 22 |
also significantly | 22 |
derived platelets | 22 |
total cost | 22 |
following transfusion | 22 |
breast milk | 22 |
quality controls | 22 |
allergic rhinoconjunctivitis | 22 |
readily available | 22 |
months prior | 22 |
fold higher | 22 |
mass index | 22 |
information systems | 21 |
using pcr | 21 |
group ii | 21 |
pediatric population | 21 |
genotyping results | 21 |
vista tm | 21 |
rbc products | 21 |
case series | 21 |
platelet activation | 21 |
patient reported | 21 |
study will | 21 |
three blood | 21 |
serum cobalamin | 21 |
bacterial pathogens | 21 |
testing may | 21 |
data demonstrate | 21 |
lymphocyte count | 21 |
virus growth | 21 |
significant proportion | 21 |
systemic reactions | 21 |
binding sites | 21 |
high concentrations | 21 |
nk cell | 21 |
magnetic cards | 21 |
clinical status | 21 |
apheresis procedure | 21 |
cancer cells | 21 |
health conditions | 21 |
effective use | 21 |
febrile non | 21 |
routine clinical | 21 |
ae sd | 21 |
hospital capacity | 21 |
many different | 21 |
rate rgn | 21 |
years period | 21 |
rhd gamma | 21 |
donor platelets | 21 |
adverse transfusion | 21 |
predonation hb | 21 |
symptomatic individuals | 21 |
sublingual immunotherapy | 21 |
gamma irradiation | 21 |
adverse outcomes | 21 |
restrictive transfusion | 21 |
new technologies | 21 |
transgenic mice | 21 |
give blood | 21 |
low ferritin | 21 |
throat swabs | 21 |
polyclonal anti | 21 |
data set | 21 |
study using | 21 |
mrsa strains | 21 |
lockdown measures | 21 |
dna testing | 21 |
slightly lower | 21 |
shear stress | 21 |
dat positive | 21 |
health workers | 21 |
transfusion chain | 21 |
may allow | 21 |
autoimmune diseases | 21 |
respiratory infection | 21 |
cd deficiency | 21 |
pool testing | 21 |
took place | 21 |
immature platelet | 21 |
hand hygiene | 21 |
transfusion guidelines | 21 |
clinical picture | 21 |
blood ordering | 21 |
within min | 21 |
useful tool | 21 |
serial dilutions | 21 |
thrombocytopenic patients | 21 |
test foods | 21 |
disease transmission | 21 |
gram stain | 21 |
old individuals | 21 |
side effect | 21 |
auc mic | 21 |
sexual partners | 21 |
literature review | 21 |
retrospective chart | 21 |
serum igg | 21 |
typing results | 21 |
test data | 21 |
expected number | 21 |
platelet rich | 21 |
evidence suggests | 21 |
final concentration | 21 |
antibacterial activity | 21 |
platelet loss | 21 |
primed donor | 21 |
disease progression | 21 |
allergic subjects | 21 |
three studies | 21 |
hong kong | 21 |
positive effect | 21 |
finger prick | 21 |
antibiotic use | 21 |
drinking water | 21 |
serological test | 21 |
upper limit | 21 |
higher frequency | 21 |
transfusion strategy | 21 |
anaphylactic shock | 21 |
adipose tissue | 21 |
blood mononuclear | 21 |
critical role | 21 |
total score | 21 |
allergic conjunctivitis | 21 |
treponema pallidum | 21 |
cardiac function | 21 |
group compared | 21 |
young adults | 21 |
mainly due | 21 |
high doses | 21 |
zikv rna | 20 |
wbc counts | 20 |
emergency blood | 20 |
iron metabolism | 20 |
allergy clinic | 20 |
group tests | 20 |
cell concentrate | 20 |
control horses | 20 |
may include | 20 |
virus load | 20 |
oral iron | 20 |
return rates | 20 |
biopsy specimens | 20 |
molecular typing | 20 |
hek cells | 20 |
laboratory information | 20 |
low cost | 20 |
case group | 20 |
metal nanoparticles | 20 |
member states | 20 |
plasma using | 20 |
laboratory medicine | 20 |
serum iron | 20 |
tests showed | 20 |
cardiac disease | 20 |
total population | 20 |
hospital patients | 20 |
otherwise healthy | 20 |
simultaneous detection | 20 |
replacement donors | 20 |
antigen negative | 20 |
serology tests | 20 |
american society | 20 |
methods used | 20 |
positive rates | 20 |
bacterial infection | 20 |
quantitative real | 20 |
general anesthesia | 20 |
mean serum | 20 |
allowed us | 20 |
academic year | 20 |
scale testing | 20 |
new tests | 20 |
showed similar | 20 |
time rt | 20 |
allergic contact | 20 |
tree nut | 20 |
dna repair | 20 |
plasma membrane | 20 |
hybrid rhesus | 20 |
signal generation | 20 |
samples using | 20 |
diagnostic criteria | 20 |
cardiac hypertrophy | 20 |
skin rash | 20 |
test line | 20 |
central blood | 20 |
culture media | 20 |
cross reactivity | 20 |
samples showed | 20 |
volunteer donors | 20 |
high degree | 20 |
two dogs | 20 |
canadian blood | 20 |
mrsa isolates | 20 |
leucocyte depleted | 20 |
serologic tests | 20 |
transfusion institute | 20 |
evidence based | 20 |
stored rbcs | 20 |
inflammatory response | 20 |
rna detection | 20 |
premature infants | 20 |
receptor activation | 20 |
clostridium difficile | 20 |
marrow transplant | 20 |
protective equipment | 20 |
respiratory failure | 20 |
nasal mucosa | 20 |
transmitted diseases | 20 |
prick testing | 20 |
positive individuals | 20 |
findings indicate | 20 |
see appendix | 20 |
long time | 20 |
sensitive detection | 20 |
core antigen | 20 |
dtt treatment | 20 |
tissue samples | 20 |
mean score | 20 |
roche cobas | 20 |
patients using | 20 |
supplementary table | 20 |
respiratory panel | 20 |
covid patients | 20 |
antibody prevalence | 20 |
symptom scores | 20 |
microbiological quality | 20 |
plt transfusions | 20 |
results indicated | 20 |
months post | 20 |
donor plasma | 20 |
group i | 20 |
community hospital | 20 |
presented data | 20 |
using data | 20 |
oral challenge | 20 |
detected using | 20 |
may suggest | 20 |
timely manner | 20 |
will lead | 20 |
clinically important | 20 |
latex allergy | 20 |
potassium level | 20 |
confounding factors | 20 |
two studies | 20 |
tidal volume | 20 |
manual method | 20 |
blood plasma | 20 |
data showed | 20 |
risk perception | 20 |
rhd variant | 20 |
molecular biology | 20 |
times per | 20 |
effective therapy | 20 |
laryngeal edema | 20 |
food challenge | 20 |
rh blood | 20 |
four years | 20 |
old boy | 20 |
atopic patients | 20 |
hematopoietic cells | 19 |
positive ana | 19 |
detection limits | 19 |
day post | 19 |
much less | 19 |
health systems | 19 |
gold nanoparticle | 19 |
rh system | 19 |
may reduce | 19 |
animal testing | 19 |
strand breaks | 19 |
national haemovigilance | 19 |
coupled receptor | 19 |
widespread use | 19 |
potential donors | 19 |
iron status | 19 |
test may | 19 |
complete resolution | 19 |
bronchoalveolar lavage | 19 |
new therapeutic | 19 |
infection rates | 19 |
transfusion support | 19 |
body temperature | 19 |
rhd zygosity | 19 |
two tests | 19 |
low number | 19 |
closed system | 19 |
innate immunity | 19 |
high school | 19 |
signal transduction | 19 |
assisted laser | 19 |
also determined | 19 |
found positive | 19 |
rapid testing | 19 |
using elisa | 19 |
screening method | 19 |
selectin expression | 19 |
antimicrobial stewardship | 19 |
chronic inflammatory | 19 |
molecular analysis | 19 |
asthma diagnosis | 19 |
wallis test | 19 |
average positivity | 19 |
three weeks | 19 |
lateral sclerosis | 19 |
procleix ultrio | 19 |
platelet collection | 19 |
healthy horses | 19 |
donor health | 19 |
tested patients | 19 |
university medical | 19 |
different stages | 19 |
detection threshold | 19 |
epidemiological studies | 19 |
acid sequence | 19 |
new approach | 19 |
agar plates | 19 |
million inhabitants | 19 |
human blood | 19 |
additional data | 19 |
mic ratio | 19 |
rh antigens | 19 |
io catheter | 19 |
local blood | 19 |
lactate production | 19 |
igm igg | 19 |
homologous blood | 19 |
following criteria | 19 |
ad patients | 19 |
rural areas | 19 |
irregular antibodies | 19 |
received blood | 19 |
mean volume | 19 |
discrepant results | 19 |
four months | 19 |
study performed | 19 |
additional studies | 19 |
basophil activation | 19 |
mic values | 19 |
quality indicators | 19 |
tests required | 19 |
available data | 19 |
th percentile | 19 |
study provides | 19 |
free dna | 19 |
data file | 19 |
alkaline phosphatase | 19 |
total plasma | 19 |
expiratory flow | 19 |
previous study | 19 |
may reflect | 19 |
middle east | 19 |
vitro methods | 19 |
detection using | 19 |
panel cells | 19 |
neurological association | 19 |
laboratory services | 19 |
significant change | 19 |
tumor cells | 19 |
rgn initial | 19 |
american neurological | 19 |
platelet inventory | 19 |
low rate | 19 |
higher rate | 19 |
image analysis | 19 |
donors aged | 19 |
case illustrates | 19 |
posterior distribution | 19 |
task force | 19 |
previous years | 19 |
descriptive statistics | 19 |
hospital based | 19 |
amyotrophic lateral | 19 |
specific antigens | 19 |
hiv ag | 19 |
test kits | 19 |
care units | 19 |
blood sampling | 19 |
social media | 19 |
made using | 19 |
molecular basis | 19 |
male donor | 19 |
every weeks | 19 |
amotosalen uva | 19 |
flow immunoassay | 19 |
physical distancing | 19 |
mitral valve | 19 |
several days | 19 |
theragnostic tests | 19 |
antibody specificity | 19 |
serum periostin | 19 |
pd patients | 19 |
syphilis screening | 19 |
species level | 19 |
receptor antagonist | 19 |
showed high | 19 |
kg dose | 19 |
toxic effects | 19 |
skin biopsy | 19 |
oral food | 19 |
infected donors | 19 |
ag ab | 19 |
malaria diagnosis | 19 |
health sciences | 19 |
immunosuppressive therapy | 19 |
uncontrolled asthma | 19 |
additional testing | 19 |
igm positive | 19 |
health policy | 19 |
hla typing | 19 |
transfusion trigger | 19 |
blood conservation | 19 |
intrauterine transfusions | 19 |
desorption ionization | 19 |
patients presenting | 19 |
medical practice | 19 |
graft versus | 19 |
primer pairs | 19 |
null hypothesis | 19 |
model parameters | 19 |
nasal swabs | 19 |
data will | 19 |
positivity rates | 18 |
inflammatory bowel | 18 |
cold antibodies | 18 |
patient sample | 18 |
survival time | 18 |
ethics committee | 18 |
different tests | 18 |
least days | 18 |
blood testing | 18 |
large community | 18 |
transfusion transmission | 18 |
igg molecules | 18 |
anemic patients | 18 |
research institute | 18 |
free haemoglobin | 18 |
antibodies anti | 18 |
del phenotype | 18 |
blood stem | 18 |
skeletal muscle | 18 |
alert system | 18 |
young age | 18 |
drug resistant | 18 |
different levels | 18 |
rbc collection | 18 |
normal controls | 18 |
major surgery | 18 |
normal distribution | 18 |
hla antibody | 18 |
process time | 18 |
tube testing | 18 |
online survey | 18 |
positive individual | 18 |
detection method | 18 |
cell panel | 18 |
culture bottles | 18 |
serological assays | 18 |
multiple transfusions | 18 |
rhd variants | 18 |
antiviral activity | 18 |
normally distributed | 18 |
testing program | 18 |
vitro model | 18 |
care hospital | 18 |
resonance imaging | 18 |
based assay | 18 |
one donor | 18 |
tested samples | 18 |
ns ns | 18 |
direct detection | 18 |
fuzzy data | 18 |
transfusion committee | 18 |
severe persistent | 18 |
hyperthyroid cats | 18 |
virus transmission | 18 |
odor identification | 18 |
clinical situations | 18 |
staphylococcus epidermidis | 18 |
group received | 18 |
quantitative pcr | 18 |
wt wt | 18 |
covid hospital | 18 |
lower limit | 18 |
last decade | 18 |
optimised scansystem | 18 |
clinical evidence | 18 |
internal controls | 18 |
methylene blue | 18 |
nucleotide polymorphisms | 18 |
educational level | 18 |
ige antibodies | 18 |
two hours | 18 |
lst system | 18 |
death rate | 18 |
laboratory practice | 18 |
hev rna | 18 |
general hospitals | 18 |
hematology analyzer | 18 |
healthcare systems | 18 |
assess whether | 18 |
detection systems | 18 |
odds ratios | 18 |
patients requiring | 18 |
commercial laboratories | 18 |
pulmonary hypertension | 18 |
plasma concentration | 18 |
preoperative autologous | 18 |
considered positive | 18 |
well understood | 18 |
unit testing | 18 |
nat testing | 18 |
reference method | 18 |
since last | 18 |
west nile | 18 |
tests using | 18 |
based blood | 18 |
transfused units | 18 |
short time | 18 |
screening results | 18 |
energy transfer | 18 |
likely due | 18 |
human health | 18 |
dtc covid | 18 |
grade i | 18 |
less severe | 18 |
test monotonicity | 18 |
transfusion hepatitis | 18 |
wb units | 18 |
severe cases | 18 |
four weeks | 18 |
raw materials | 18 |
become available | 18 |
provide information | 18 |
case management | 18 |
fuzzy numbers | 18 |
blood bag | 18 |
randomly assigned | 18 |
reactive oxygen | 18 |
gambro bct | 18 |
therapeutic option | 18 |
symptoms onset | 18 |
increased sensitivity | 18 |
local population | 18 |
studies included | 18 |
data support | 18 |
noble metal | 18 |
care diagnostics | 18 |
poc test | 18 |
major role | 18 |
tested rgn | 18 |
poc diagnostics | 18 |
better understanding | 18 |
leukocyte antibodies | 18 |
showed higher | 18 |
low blood | 18 |
virus type | 18 |
among non | 18 |
igg igm | 18 |
photochemical treatment | 18 |
cell transfusions | 18 |
asymptomatic screening | 18 |
management systems | 18 |
rapid point | 18 |
partial ds | 18 |
treated red | 18 |
cytotoxic effects | 18 |
standard test | 18 |
mds patients | 18 |
disease diagnostics | 18 |
proinflammatory cytokines | 18 |
therapeutic approach | 18 |
mg qd | 18 |
rhd exon | 18 |
asymptomatic fraction | 18 |
operative infections | 18 |
coronary artery | 18 |
architect i | 18 |
emerging infectious | 18 |
cat dander | 18 |
published literature | 18 |
theraflex mb | 18 |
transfusion laboratory | 18 |
directive ec | 18 |
coagulation parameters | 18 |
case definition | 18 |
commonly encountered | 18 |
th centile | 18 |
sudden sensorineural | 18 |
lower respiratory | 18 |
elderly patients | 18 |
laboratory utilization | 18 |
alternative methods | 18 |
hospitalized rgn | 18 |
bile acid | 18 |
serum creatinine | 18 |
increased susceptibility | 18 |
minimum inhibitory | 18 |
relatively small | 18 |
monolisa hcv | 18 |
test systems | 18 |
seasonal influenza | 18 |
donor retention | 18 |
diagnostic performance | 18 |
patients died | 18 |
clinical importance | 18 |
autovue innova | 18 |
hcv nat | 18 |
hbv nat | 18 |
study conducted | 18 |
catheter insertion | 18 |
using standard | 18 |
sensitized patients | 18 |
outcome review | 18 |
type diabetes | 18 |
poorly understood | 18 |
inh titre | 18 |
allele frequencies | 18 |
colony forming | 17 |
hb values | 17 |
negative donors | 17 |
south african | 17 |
female donor | 17 |
automated testing | 17 |
rhd immunization | 17 |
estimated using | 17 |
samples taken | 17 |
platelet specific | 17 |
cytokine production | 17 |
health measures | 17 |
following treatment | 17 |
storage duration | 17 |
pf antibody | 17 |
two consecutive | 17 |
also seen | 17 |
test program | 17 |
nasal polyposis | 17 |
cd high | 17 |
free diet | 17 |
another study | 17 |
severe reaction | 17 |
significantly correlated | 17 |
procedures performed | 17 |
rating scale | 17 |
study investigated | 17 |
clart pneumovir | 17 |
gestational age | 17 |
transferrin saturation | 17 |
nosocomial infections | 17 |
patients diagnosed | 17 |
transcription factors | 17 |
donor platelet | 17 |
data available | 17 |
one rbc | 17 |
antibody screens | 17 |
tube methods | 17 |
second group | 17 |
evaluate whether | 17 |
oxygen species | 17 |
additional tests | 17 |
dat negative | 17 |
matched controls | 17 |
approved cleared | 17 |
rapid molecular | 17 |
individual tests | 17 |
cmv igg | 17 |
oral administration | 17 |
cell lymphoma | 17 |
among women | 17 |
higher among | 17 |
treatment option | 17 |
different time | 17 |
chi square | 17 |
demographic data | 17 |
cells expressing | 17 |
gel card | 17 |
identified using | 17 |
net rgn | 17 |
currently used | 17 |
pcr positive | 17 |
haemolytic transfusion | 17 |
controlled clinical | 17 |
disease dynamics | 17 |
random donor | 17 |
positively tested | 17 |
donors will | 17 |
protein synthesis | 17 |
international guidelines | 17 |
repeated blood | 17 |
titer anti | 17 |
epithelial cell | 17 |
test capacity | 17 |
oxygen delivery | 17 |
information obtained | 17 |
cardiac fibroblasts | 17 |
data concerning | 17 |
many studies | 17 |
high rates | 17 |
next step | 17 |
studies suggest | 17 |
volume processed | 17 |
also evaluated | 17 |
observed data | 17 |
recurrent infections | 17 |
serious complications | 17 |
decision support | 17 |
human lung | 17 |
rejuvenation solution | 17 |
immediate spin | 17 |
every days | 17 |
clinical conditions | 17 |
reported symptoms | 17 |
southeast asia | 17 |
term care | 17 |
cow milk | 17 |
natural history | 17 |
laboratory staff | 17 |
high number | 17 |
positive bacteria | 17 |
selected patients | 17 |
randomised controlled | 17 |
correlation coefficient | 17 |
seven patients | 17 |
agar dilution | 17 |
hbc negative | 17 |
hospital background | 17 |
significant role | 17 |
cell type | 17 |
igg antibody | 17 |
manufacturing process | 17 |
angiotensin ii | 17 |
transfusion strategies | 17 |
pollen counts | 17 |
multivariate analysis | 17 |
five percent | 17 |
anaplasma phagocytophilum | 17 |
volunteer blood | 17 |
i sr | 17 |
slightly higher | 17 |
new method | 17 |
cell salvage | 17 |
western blotting | 17 |
also known | 17 |
collected data | 17 |
transcript levels | 17 |
recent study | 17 |
pool designs | 17 |
patient underwent | 17 |
spike protein | 17 |
ae ml | 17 |
testing procedures | 17 |
ground truth | 17 |
rhinitis patients | 17 |
viral respiratory | 17 |
days storage | 17 |
high cost | 17 |
pol ii | 17 |
plasma replacement | 17 |
normal levels | 17 |
perceived risk | 17 |
erythrocyte concentrates | 17 |
detection probes | 17 |
reinforced composites | 17 |
cell antibody | 17 |
blood centres | 17 |
every months | 17 |
will facilitate | 17 |
microsatellite instability | 17 |
coupled receptors | 17 |
molecular test | 17 |
pancreatic cancer | 17 |
retrospective cohort | 17 |
autoimmune haemolytic | 17 |
without clinical | 17 |
cardiac remodeling | 17 |
assay using | 17 |
facs analysis | 17 |
test using | 17 |
pcr method | 17 |
silver enhancement | 17 |
increased number | 17 |
desensitization protocol | 17 |
receive blood | 17 |
statistical analyses | 17 |
macrolide resistance | 17 |
correct diagnosis | 17 |
vox sang | 17 |
donations per | 17 |
susceptible population | 17 |
test goals | 17 |
inflammatory diseases | 17 |
skin lesions | 17 |
mean duration | 17 |
see chapter | 17 |
receiver operating | 17 |
myeloid leukemia | 17 |
rank test | 17 |
voluntary non | 17 |
von willebrand | 17 |
extracellular matrix | 17 |
cell patients | 17 |
vitro diagnostic | 17 |
closely related | 17 |
may induce | 17 |
showed increased | 17 |
rna testing | 17 |
ethylene glycol | 17 |
third generation | 17 |
two additional | 17 |
antibodies using | 17 |
poc testing | 17 |
million donations | 17 |
clinical information | 17 |
amplification tests | 17 |
treatment options | 17 |
antigen typing | 17 |
patients included | 17 |
serum cortisol | 16 |
transfusion purpura | 16 |
different regions | 16 |
interpreted according | 16 |
rbc alloimmunization | 16 |
transfusion protocols | 16 |
cell apheresis | 16 |
primary studies | 16 |
allergic response | 16 |
individual donation | 16 |
potential benefits | 16 |
response rates | 16 |
turnaround times | 16 |
outpatient clinic | 16 |
beckman coulter | 16 |
elisa test | 16 |
th week | 16 |
year history | 16 |
generalized urticaria | 16 |
flow chart | 16 |
adoption rates | 16 |
hcv antibody | 16 |
main reason | 16 |
lower sensitivity | 16 |
one dog | 16 |
allergen exposure | 16 |
irregular antibody | 16 |
ko mice | 16 |
rhd alleles | 16 |
months old | 16 |
hospitalized infectious | 16 |
clinical diagnostics | 16 |
one third | 16 |
regulatory requirements | 16 |
cells treated | 16 |
definitive diagnosis | 16 |
physical activity | 16 |
time since | 16 |
simplex virus | 16 |
rbc exchange | 16 |
severe transfusion | 16 |
female patients | 16 |
viral culture | 16 |
validation studies | 16 |
significantly less | 16 |